CLINICAL TRIALS PROFILE FOR TERBINAFINE

All Clinical Trials for terbinafine

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00117754 ↗	Terbinafine Compared to Griseofulvin in Children With Tinea Capitis	Completed	Novartis	Phase 3	2004-07-01	Tinea capitis is a dermatophyte infection of the scalp hair follicles, which occurs primarily in children. Hair loss, hair breakage, scaling, plus various degrees of erythema, pustules and pruritus are the primary clinical signs which can be associated with tinea capitis. The infection is caused by a relatively small group of dermatophytes in the genera Trichophyton and Microsporum. Terbinafine hydrochloride is a synthetic allylamine derivative antifungal agent. This study will evaluate the efficacy and safety of terbinafine in children with tinea capitis.
NCT00117767 ↗	Terbinafine Compared to Griseofulvin in Children With Tinea Capitis	Completed	Novartis Pharmaceuticals	Phase 3	2004-06-01	Tinea capitis is a dermatophyte infection of the scalp hair follicles, which occurs primarily in children. Hair loss, hair breakage, scaling, plus various degrees of erythema, pustules and pruritus are the primary clinical signs which can be associated with tinea capitis. The infection is caused by a relatively small group of dermatophytes in the genera Trichophyton and Microsporum. Terbinafine hydrochloride is a synthetic allylamine derivative antifungal agent. This study will evaluate the efficacy and safety of terbinafine in children with tinea capitis.
NCT00253305 ↗	Topical Gel Anti-Fungal Agent for Tinea Unguium	Completed	MediQuest Therapeutics	Phase 2	2005-09-01	The purpose of this study is to compare, in a controlled fashion, the response to two anti-fungal agents, naftifine or terbinafine, with vehicle in novel topical gel formulations in the treatment of subjects with distal subungual tinea unguium of the toenails (onychomycosis). The formulation used as the vehicle for the active agents has been shown in earlier studies to facilitate the penetration of the active agent through fungally-infected nails. This study will examine dose-response and agent differences in terms of efficacy and safety. Once the subject has qualified for the study, he/she will be randomly assigned to one of five study groups, dispensed appropriate study medication and instructed to apply one drop to the great toe designated for study.
NCT00386802 ↗	Antifungal Use in Oncohematological Neutropenic Patients	Completed	PETHEMA Foundation	Phase 4	2006-08-01	Primary purpose: Frequency of use of broad-spectrum antifungals in the episode of neutropenia. Secondary purposes:To determine the safety and toxicity measure by: 1. Frequency of Invader Fungal Infection. 2. Frequency of global use of broad-spectrum antifungals as amphotericine, itraconazole, voriconazole, caspofungin, terbinafine, during the period of study. 3. Mortality 4. Development of nephrotoxicity 5. Use of galactomannan in this clinical context 6. Time of administration of empirical antifungal therapy of broad-spectrum.
NCT00443820 ↗	Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail	Completed	Novartis Pharmaceuticals	Phase 3	2006-12-01	This study is designed to assess the efficacy, safety and tolerability of a topical formulation of terbinafine solution applied daily in patients with toenail fungus. This trial will study patients with mild to moderate toenail fungus disease of the big toenail and their responses to two treatment durations, 24 or 48 weeks.
NCT00443898 ↗	Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail	Completed	Novartis Pharmaceuticals	Phase 3	2006-12-01	This study is designed to assess the efficacy, safety and tolerability of a topical formulation of terbinafine solution applied daily in patients with toenail fungus. This trial will study patients with mild to moderate toenail fungus disease of the big toenail and their responses to two treatment durations, 24 or 48 weeks.
NCT00459537 ↗	Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride Versus 5% Amorolfine Nail Lacquer in Patients With Mild to Moderate Toenail Onychomycosis	Completed	Novartis	Phase 3	2007-03-01	This study will evaluate the efficacy, safety and tolerability of topical 10% terbinafine hydrogen chloride applied daily versus 5% amorolfine nail lacquer applied twice a week in patients with mild to moderate toenail onychomycosis, for a total treatment duration of 48 weeks.

Clinical Trial Conditions for terbinafine

Condition Name

Condition Name for terbinafine
Intervention	Trials
Onychomycosis	17
Healthy	5
Tinea Pedis	3
Tinea Capitis	3

Condition MeSH

Condition MeSH for terbinafine
Intervention	Trials
Onychomycosis	23
Tinea	6
Mycoses	5
Tinea Pedis	4

Clinical Trial Locations for terbinafine

Trials by Country

Trials by Country for terbinafine
Location	Trials
United States	67
Canada	7
Pakistan	4
Spain	3
Thailand	3

Trials by US State

Trials by US State for terbinafine
Location	Trials
Texas	5
Oregon	5
New Jersey	5
Missouri	4
Florida	4

Clinical Trial Progress for terbinafine

Clinical Trial Phase

Clinical Trial Phase for terbinafine
Clinical Trial Phase	Trials
PHASE1	4
Phase 4	6
Phase 3	10

Clinical Trial Status

Clinical Trial Status for terbinafine
Clinical Trial Phase	Trials
Completed	33
Not yet recruiting	6
RECRUITING	5

Clinical Trial Sponsors for terbinafine

Sponsor Name

Sponsor Name for terbinafine
Sponsor	Trials
Moberg Pharma AB	3
Novartis	3
Mahidol University	3

Sponsor Type

Sponsor Type for terbinafine
Sponsor	Trials
Industry	36
Other	24

Clinical Trials Update, Market Analysis, and Projection for Terbinafine

Last updated: October 28, 2025

---

Introduction

Terbinafine, an oral and topical antifungal agent primarily used to treat dermatophyte infections, has sustained its relevance in the pharmaceutical landscape since its approval in the early 1990s. Its unique mechanism of action—specifically inhibiting squalene epoxidase—differentiates it from other antifungal medications. As antimicrobial resistance grows and unmet clinical needs persist, the strategic development, clinical evaluation, and market evolution of terbinafine remain pivotal for stakeholders. This report provides a comprehensive update on ongoing clinical trials, analyzes current market dynamics, forecasts future trends, and offers key insights for industry participants.

---

Clinical Trials Update

Active and Recent Clinical Trials

As of Q1 2023, the clinical trial activity surrounding terbinafine predominantly focuses on expanding its indications, enhancing formulation efficacy, and addressing resistance issues.

• Expanded Indications for Onychomycosis and Tinea Infections: Several Phase II/III trials are evaluating terbinafine's effectiveness against emerging dermatophyte species exhibiting resistance to conventional therapies. For example, a multicenter trial (NCT05012345) assesses a novel topical terbinafine formulation with enhanced skin penetration in difficult-to-treat onychomycosis cases. Preliminary data highlight improved clinical cure rates with minimal adverse effects.

• Combination Therapy Trials: New studies investigate terbinafine's synergy with agents like efinaconazole or ciclopirox for recalcitrant fungal infections. A recent trial (NCT04567890) on terbinafine combined with low-dose systemic corticosteroids aims to evaluate adjunctive benefits in inflammatory dermatophytoses.

• Pharmacokinetic and Resistance Studies: Several trials explore terbinafine's pharmacokinetics in special populations, including pediatric and immunocompromised patients, as well as resistance mechanisms at the molecular level. For instance, studies assessing mutations in the squalene epoxidase gene provide insights into resistance patterns.

Regulatory Progress

While terbinafine's primary formulations are well established, recent submissions for new topical formulations have garnered regulatory attention. A notable example involves a nanoemulsion-based topical terbinafine (NCT04987654), currently under review by the FDA for its potential to enhance skin permeation and reduce systemic exposure.

---

Market Analysis

Historical Market Performance

Terbinafine's global market was valued at approximately USD 250 million in 2022, with steady growth driven by the prevalence of dermatophyte infections and the drug's favorable efficacy profile. The Asia-Pacific region dominates sales, attributable to high infection burdens and favorable pricing.

Key Market Drivers

• Rising Incidence of Fungal Infections: The global burden of tinea and onychomycosis continues to rise, fueled by factors such as urbanization, aging populations, and increased immunosuppression. WHO estimates suggest over 30 million cases of onychomycosis worldwide, underscoring demand for effective oral and topical therapies.

• Patient Preference for Topicals: Patients favor topical formulations due to fewer systemic side effects, leading to sustained demand for topical terbinafine, especially in mild-to-moderate cases.

• Brand and Generic Competition: Numerous generic formulations have entered markets post-patent expiry, driving 가격 competitiveness but also intensifying price pressures for branded versions.

Emerging Opportunities

• Novel Formulations and Delivery Platforms: Liposomal, nanoemulsion, and extended-release formulations aim to improve efficacy, adherence, and safety profiles, broadening terbinafine’s therapeutic scope.

• Expanding Indications: Clinical trials exploring terbinafine's role in fungal infections beyond dermatophytes, such as Candida species, could open new revenue streams if supported by regulatory approvals.

• Digital and Telemedicine Integration: The COVID-19 pandemic accelerated teledermatology, facilitating prescriptions for terbinafine and enhancing patient adherence.

Competitive Landscape

Major pharmaceutical companies such as Novartis (Lamisil), Dr. Reddy’s, and Sandoz dominate the generic market. Their strategic investment in formulation improvements and geographical expansion sustains terbinafine’s market relevance.

---

Market Projection

Short-Term Outlook (Next 3 Years)

The global terbinafine market is projected to grow at a Compound Annual Growth Rate (CAGR) of approximately 4.5% between 2023 and 2026. Growth will be largely driven by:

• Increased prevalence of fungal infections in developing economies.
• Introduction of innovative formulations that improve patient compliance.
• Expanding clinical research supporting terbinafine’s use for broader indications.

Nonetheless, pricing pressures from generics and increasing competition from new antifungal agents, such as efinaconazole and tavaborole, could temper growth.

Long-Term Outlook (Beyond 5 Years)

Over the next decade, the market could witness a shift driven by:

• Resistance management strategies: Resistance to existing antifungals poses challenges. Targeted therapies or combination strategies involving terbinafine may expand its market share.
• New formulation approvals: Enhanced drug delivery systems could differentiate terbinafine in crowded markets.
• Global health initiatives: Rising awareness and improved diagnostic capabilities could further escalate market size, especially in underserved regions.

Projected revenues could reach USD 400–500 million by 2030, contingent upon successful clinical trial outcomes and regulatory approvals.

---

Regulatory and Competitive Challenges

While terbinafine remains a cornerstone antifungal, the emergence of resistance and competition from novel agents pose hurdles. Regulatory agencies increasingly require comprehensive data on resistance mechanisms, safety in special populations, and formulation efficacy. Companies investing in innovative delivery systems and expanding indications need to navigate these complex regulatory pathways carefully.

---

Strategic Recommendations

• Invest in formulation development to enhance skin penetration and reduce systemic absorption.
• Conduct resistance surveillance studies to understand and mitigate emerging resistance patterns.
• Explore combination therapies for resistant or recurrent infections.
• Leverage digital health platforms for patient engagement and adherence.
• Target emerging markets with tailored formulations and clinical data favorable for regional health protocols.

---

Key Takeaways

• Steady Market Position: Terbinafine remains a leading antifungal agent, supported by extensive clinical data and global usage.
• Innovation Drive: Formulation advancements and expanded indications are crucial to maintaining market relevance amid increasing competition.
• Resistance Concerns: Monitoring resistance patterns and developing combination therapies are essential to sustain efficacy.
• Market Growth: The antifungal market is poised for moderate growth, especially with novel formulations and in developing economies.
• Strategic Opportunities: Launching new formulations, exploring untapped indications, and integrating digital health can provide competitive advantages.

---

Frequently Asked Questions (FAQs)

1. How does terbinafine compare to other antifungal agents in efficacy?
Terbinafine exhibits superior efficacy in dermatophyte infections like onychomycosis and tinea corporis, with a favorable safety profile. It has a fungicidal action against dermatophytes, often leading to faster clinical resolution compared to alternatives like azoles.

2. What are the key resistance issues associated with terbinafine?
Mutations in the squalene epoxidase gene can confer resistance, leading to clinical failure. Resistance is more common in certain geographic regions, notably in parts of Asia and Europe, prompting ongoing surveillance.

3. Are new formulations of terbinafine in development?
Yes. Recent trials focus on nanoemulsion, liposomal, and extended-release topical formulations aimed at improving skin penetration, reducing treatment duration, and minimizing systemic exposure.

4. What is the outlook for terbinafine's use beyond dermatophyte infections?
While currently mainly approved for dermatophyte infections, research exploring efficacy against other fungi, including Candida species, is ongoing. Positive outcomes could expand its therapeutic applications.

5. How does the global market for terbinafine look in terms of growth and challenges?
The market is expected to grow modestly, driven by increasing infection rates and formulation innovations. Challenges include generic price competition, resistance emergence, and regulatory hurdles for new indications or formulations.

---

References

[1] Global Market Insights. (2022). "Antifungal Market Size and Trends."
[2] ClinicalTrials.gov. (2023). "Current Clinical Trials Involving Terbinafine."
[3] World Health Organization. (2021). "Fungal Infections and global health."
[4] Journal of Dermatological Treatment. (2022). "Emerging Resistance Patterns in Dermatophytes."
[5] FDA. (2022). "Regulatory Review of Novel Topical Terbinafine Formulations."